Creative Medical Technology Holdings Inc (CELZ)

[uvaphd]

Right-to-Try law and CELZ. I believe this will have potentially MASSIVE impact on the StemSpine segment
of the business. Those tens of thousands (millions?) who suffer from chronic back pain due to DDD may well be able to elect this procedure AND have it paid for by insurance (and near in mind that our QUITE quiet communicators just told us to expect commercialization of StemSpine in Q4 2019–i.e. in the next 2-3 months!). Now THAT could be MASSIVE here—and would put another crimp in the style of the opioid pushers...